

Francesca Battaglin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7118338/publications.pdf>

Version: 2024-02-01

129
papers

2,043
citations

279487

23
h-index

276539

41
g-index

130
all docs

130
docs citations

130
times ranked

3690
citing authors

#	ARTICLE	IF	CITATIONS
1	Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels. <i>Journal of Clinical Oncology</i> , 2016, 34, 2141-2147.	0.8	204
2	Outlooks on Epstein-Barr virus associated gastric cancer. <i>Cancer Treatment Reviews</i> , 2018, 66, 15-22.	3.4	149
3	Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 2414-2422.	3.2	148
4	B cell and B cell-related pathways for novel cancer treatments. <i>Cancer Treatment Reviews</i> , 2019, 73, 10-19.	3.4	132
5	Molecular insight of regorafenib treatment for colorectal cancer. <i>Cancer Treatment Reviews</i> , 2019, 81, 101912.	3.4	109
6	Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer. <i>Oncologist</i> , 2016, 21, 988-994.	1.9	94
7	Safety and Tolerability of c-MET Inhibitors in Cancer. <i>Drug Safety</i> , 2019, 42, 211-233.	1.4	76
8	Molecular Profiling of Appendiceal Adenocarcinoma and Comparison with Right-sided and Left-sided Colorectal Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 3096-3103.	3.2	65
9	Molecular profile of BRCA-mutated biliary tract cancers. <i>ESMO Open</i> , 2020, 5, e000682.	2.0	64
10	Microsatellite instability in colorectal cancer: overview of its clinical significance and novel perspectives. <i>Clinical Advances in Hematology and Oncology</i> , 2018, 16, 735-745.	0.3	59
11	Comprehensive Genomic Profiling of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs). <i>Clinical Cancer Research</i> , 2020, 26, 5943-5951.	3.2	55
12	Colorectal cancer: epigenetic alterations and their clinical implications. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2017, 1868, 439-448.	3.3	48
13	Molecular biomarkers in gastro-esophageal cancer: recent developments, current trends and future directions. <i>Cancer Cell International</i> , 2018, 18, 99.	1.8	48
14	Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram. <i>Annals of Oncology</i> , 2017, 28, 555-561.	0.6	43
15	The role of tumor angiogenesis as a therapeutic target in colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 251-266.	1.1	41
16	Clocking cancer: the circadian clock as a target in cancer therapy. <i>Oncogene</i> , 2021, 40, 3187-3200.	2.6	41
17	The impact of ARID1A mutation on molecular characteristics in colorectal cancer. <i>European Journal of Cancer</i> , 2020, 140, 119-129.	1.3	37
18	Aryl hydrocarbon receptor nuclear translocator-like (ARNTL/BMAL1) is associated with bevacizumab resistance in colorectal cancer via regulation of vascular endothelial growth factor A. <i>EBioMedicine</i> , 2019, 45, 139-154.	2.7	36

#	ARTICLE	IF	CITATIONS
19	Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world. <i>Gastric Cancer</i> , 2017, 20, 825-833.	2.7	32
20	Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies. , 2020, 8, e000404.		29
21	A new nomogram for estimating survival in patients with brain metastases secondary to colorectal cancer. <i>Radiotherapy and Oncology</i> , 2015, 117, 315-321.	0.3	28
22	Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy. <i>Oncologist</i> , 2017, 22, 1463-1469.	1.9	27
23	Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma. <i>ESMO Open</i> , 2020, 5, e000942.	2.0	26
24	Management of Advanced Small Bowel Cancer. <i>Current Treatment Options in Oncology</i> , 2018, 19, 69.	1.3	25
25	<p>The impact of panitumumab treatment on survival and quality of life in patients with RAS wild-type metastatic colorectal cancer</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 5911-5924.	0.9	25
26	Molecular Analyses of Left- and Right-Sided Tumors in Adolescents and Young Adults with Colorectal Cancer. <i>Oncologist</i> , 2020, 25, 404-413.	1.9	25
27	The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 3234-3242.	3.2	24
28	Immunogenic cell death pathway polymorphisms for predicting oxaliplatin efficacy in metastatic colorectal cancer. , 2020, 8, e001714.		23
29	Anti-EGFR monoclonal antibody panitumumab for the treatment of patients with metastatic colorectal cancer: an overview of current practice and future perspectives. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 1297-1308.	1.4	21
30	Large-scale analysis of KMT2 mutations defines a distinctive molecular subset with treatment implication in gastric cancer. <i>Oncogene</i> , 2021, 40, 4894-4905.	2.6	19
31	Molecular profiling of signet-ring-cell carcinoma (SRCC) from the stomach and colon reveals potential new therapeutic targets. <i>Oncogene</i> , 2022, 41, 3455-3460.	2.6	19
32	The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients. <i>BMC Cancer</i> , 2018, 18, 98.	1.1	17
33	Comprehensive Analysis of R-Spondin Fusions and <i>RNF43</i> Mutations Implicate Novel Therapeutic Options in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1863-1870.	3.2	16
34	Molecular Characterization of Appendiceal Goblet Cell Carcinoid. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2634-2640.	1.9	14
35	Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy. <i>Clinical Colorectal Cancer</i> , 2019, 18, e8-e19.	1.0	12
36	Frequency of BRCA mutation in biliary tract cancer and its correlation with tumor mutational burden (TMB) and microsatellite instability (MSI).. <i>Journal of Clinical Oncology</i> , 2019, 37, 4085-4085.	0.8	12

#	ARTICLE	IF	CITATIONS
37	Association of <i>BRCA</i> -mutant pancreatic cancer with high tumor mutational burden (TMB) and higher PD-L1 expression.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4133-4133.	0.8	12
38	Ramucirumab for the treatment of gastric cancers, colorectal adenocarcinomas, and other gastrointestinal malignancies. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 877-885.	1.3	11
39	WRN-Mutated Colorectal Cancer Is Characterized by a Distinct Genetic Phenotype. <i>Cancers</i> , 2020, 12, 1319.	1.7	10
40	Biomarker-driven and molecular targeted therapies for colorectal cancers. <i>Seminars in Oncology</i> , 2018, 45, 124-132.	0.8	9
41	A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trials. <i>European Journal of Cancer</i> , 2020, 131, 89-97.	1.3	9
42	Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in <i>RAS</i> / <i>BRAF</i> wild-type (wt) metastatic colorectal cancer (mCRC): Results of the phase II randomized MACBETH trial by GONO.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3543-3543.	0.8	9
43	Molecular differences between lymph nodes and distant metastases compared with primaries in colorectal cancer patients. <i>Npj Precision Oncology</i> , 2021, 5, 95.	2.3	9
44	Tandem repeat variation near the <i>HIC1</i> (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. <i>Cancer</i> , 2017, 123, 4506-4514.	2.0	8
45	Clinical Significance of Circulating Tumor Cell Induced Epithelial-Mesenchymal Transition in Patients with Metastatic Colorectal Cancer by Single-Cell RNA-Sequencing. <i>Cancers</i> , 2021, 13, 4862.	1.7	8
46	Molecular landscape of colorectal cancers harboring R-spondin fusions.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3588-3588.	0.8	7
47	Comprehensive molecular profiling of <i>IDH1/2</i> mutant biliary cancers (BC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 479-479.	0.8	7
48	Molecular characteristics and clinical outcomes of patients with Neurofibromin 1-altered metastatic colorectal cancer. <i>Oncogene</i> , 2022, 41, 260-267.	2.6	7
49	Partition: a surjective mapping approach for dimensionality reduction. <i>Bioinformatics</i> , 2020, 36, 676-681.	1.8	6
50	The landscape of DNA damage response (DDR) pathway in colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 4064-4064.	0.8	6
51	NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients. <i>PLoS ONE</i> , 2018, 13, e0193640.	1.1	5
52	Characteristics of colorectal cancer (CRC) patients with BRCA1 and BRCA2 mutations.. <i>Journal of Clinical Oncology</i> , 2019, 37, 606-606.	0.8	5
53	Pharmacogenomics in colorectal cancer: current role in clinical practice and future perspectives. <i>Journal of Cancer Metastasis and Treatment</i> , 2018, 4, 12.	0.5	5
54	Impact of polymorphisms within genes involved in regulating DNA methylation in patients with metastatic colorectal cancer enrolled in three independent, randomised, open-label clinical trials: a meta-analysis from TRIBE, MAVERICC and FIRE-3. <i>European Journal of Cancer</i> , 2019, 111, 138-147.	1.3	4

#	ARTICLE	IF	CITATIONS
55	AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC and FIRE3. <i>International Journal of Cancer</i> , 2019, 145, 2082-2090.	2.3	4
56	Modified FOLFOXIRI plus cetuximab (cet) as induction treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Preliminary results of the phase II randomized Macbeth trial by GONO group. <i>Journal of Clinical Oncology</i> , 2014, 32, 3596-3596.	0.8	4
57	Genetic variations within the CD40L immune stimulating gene predict outcome for mCRC patients treated with first-line FOLFIRI/bevacizumab: Data from FIRE-3 and TRIBE. <i>Journal of Clinical Oncology</i> , 2019, 37, 558-558.	0.8	4
58	fdrci: FDR confidence interval selection and adjustment for large-scale hypothesis testing. <i>Bioinformatics Advances</i> , 2022, 2, .	0.9	4
59	Comprehensive molecular characterization of brain metastases (BM) from colorectal cancer (CRC). <i>Annals of Oncology</i> , 2019, 30, v764.	0.6	3
60	Random survival forests identify pathways with polymorphisms predictive of survival in KRAS mutant and KRAS wild-type metastatic colorectal cancer patients. <i>Scientific Reports</i> , 2021, 11, 12191.	1.6	3
61	BRCA1 genetic variant to predict survival in metastatic colorectal cancer (mCRC) patients (pts) treated with FOLFIRI/bevacizumab (bev): Results from phase III TRIBE and FIRE-3 trials. <i>Journal of Clinical Oncology</i> , 2019, 37, 3145-3145.	0.8	3
62	Gene mutations of SWI/SNF complex and molecular profile in colorectal cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 3600-3600.	0.8	3
63	Polymorphisms in beta-defensin pathways and clinical outcomes in metastatic colorectal cancer patients treated with FOLFIRI-bevacizumab in two randomized phase III trials. <i>Journal of Clinical Oncology</i> , 2018, 36, 662-662.	0.8	3
64	Genetic variants involved in the cGAS-STING pathway predict outcome in patients with metastatic colorectal cancer: Data from FIRE-3 and TRIBE trials. <i>European Journal of Cancer</i> , 2022, 172, 22-30.	1.3	3
65	Angiogenesis inhibitors and symptomatic anal ulcers in metastatic colorectal cancer patients. <i>Acta Oncologica</i> , 2018, 57, 412-419.	0.8	2
66	Circadian clock gene PER1 mutations in colorectal cancer (CRC). <i>Journal of Clinical Oncology</i> , 2018, 36, 12106-12106.	0.8	2
67	Polymorphism in the circadian clock pathway to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from TRIBE and FIRE-3 phase III trials. <i>Journal of Clinical Oncology</i> , 2018, 36, 3576-3576.	0.8	2
68	Molecular characterization of pancreatic cancers as seen in the SLUG gene revealing cancer progression. <i>Journal of Clinical Oncology</i> , 2021, 39, 433-433.	0.8	1
69	RNA-Binding Protein Polymorphisms as Novel Biomarkers to Predict Outcomes of Metastatic Colorectal Cancer: A Meta-analysis from TRIBE, FIRE-3, and MAVERICC. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1153-1160.	1.9	1
70	Single cell RNA-sequence analysis to identify transcriptomic differences associated with treatment outcome and ethnicity in circulating tumor cells (CTCs) from patients (pts) with metastatic colorectal cancer (mCRC). <i>Journal of Clinical Oncology</i> , 2021, 39, 3041-3041.	0.8	1
71	Association of high gene expression levels of ARF6 with the immune microenvironment and prediction of poor outcomes. <i>Journal of Clinical Oncology</i> , 2021, 39, 3092-3092.	0.8	1
72	Germ line polymorphisms of genes involved in pluripotency transcription factors predict efficacy of cetuximab in metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2021, 150, 133-142.	1.3	1

#	ARTICLE	IF	CITATIONS
73	Females versus males: Clinical features and outcome differences in large molecularly selected cohort of mCRC patients.. Journal of Clinical Oncology, 2016, 34, 3540-3540.	0.8	1
74	Polymorphism in cancer-associated fibroblasts (CAFs) related genes and clinical outcome in metastatic colorectal cancer (mCRC) patients (pts) enrolled in two independent randomized phase III trials: TRIBE and FIRE-3.. Journal of Clinical Oncology, 2018, 36, 645-645.	0.8	1
75	Germline polymorphisms in genes maintaining the replication fork predict the efficacy of oxaliplatin and irinotecan in patients with metastatic colorectal cancer. British Journal of Cancer, 2021, , .	2.9	1
76	Gene expression and genetic variants in Parkinson's disease (PD) genes to predict outcome in metastatic colorectal cancer (mCRC): Data from FIRE-3 phase III trial.. Journal of Clinical Oncology, 2019, 37, 3595-3595.	0.8	1
77	Molecular differences between lymph nodes (LNs) and distant metastases (mets) in colorectal cancer (CRC).. Journal of Clinical Oncology, 2019, 37, 3130-3130.	0.8	1
78	Polymorphisms in the dopamine (DA) signaling to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from TRIBE, MAVERICC, and FIRE-3 phase III trials.. Journal of Clinical Oncology, 2019, 37, 3048-3048.	0.8	1
79	Abstract 1342: Polymorphisms in genes involved in mitophagy pathway predict clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from TRIBE and FIRE3 phase III trials. Cancer Research, 2019, 79, 1342-1342.	0.4	1
80	Variation in genetic polymorphisms and gene expression of HLA-E to predict outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with first-line FOLFIRI/cetuximab: Data from the phase III FIRE-3 trial.. Journal of Clinical Oncology, 2020, 38, 245-245.	0.8	1
81	The role of genetic variants involved with ferroptosis regulator genes in predicting outcomes in patients (pts) with RAS-mutant metastatic colorectal cancer (mCRC): Data from MAVERICC and TRIBE trials.. Journal of Clinical Oncology, 2022, 40, 197-197.	0.8	1
82	Claudin 18 (<i>CLDN18</i>) gene expression and related molecular profile in gastric cancer (GC).. Journal of Clinical Oncology, 2022, 40, 4048-4048.	0.8	1
83	Prognostic and predictive role of neutrophils/lymphocytes ratio in metastatic colorectal cancer: A retrospective analysis of the TRIBE study by Gono. Annals of Oncology, 2017, 28, iii141-iii142.	0.6	0
84	Real-world gastric cancer patients treated with at least three lines of chemotherapy: Outcomes and predictors for efficacy.. Annals of Oncology, 2017, 28, iii43-iii44.	0.6	0
85	Second-line treatment efficacy in elderly vs. non-elderly advanced gastric cancer patients: an Italian multicentre real-world study. Annals of Oncology, 2017, 28, vi45.	0.6	0
86	Genetic variants in the one-carbon metabolism pathway to predict outcome in patients with metastatic colorectal cancer (mCRC): Data from TRIBE and FIRE-3 phase III trials. Annals of Oncology, 2019, 30, v763-v764.	0.6	0
87	What Should We Do Better? Lessons from Negative Results of a Biomarker Validation Study. Journal of the National Cancer Institute, 2019, 111, 754-756.	3.0	0
88	Genetic variants involved in the lipid metabolism pathway to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from FIRE-3 and MAVERICC trials.. Journal of Clinical Oncology, 2021, 39, 118-118.	0.8	0
89	The role of PP2A variants to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from FIRE-3 and TRIBE trials.. Journal of Clinical Oncology, 2021, 39, 3581-3581.	0.8	0
90	Molecular Determinants of Gastrointestinal Cancers. Advances in Oncology, 2021, 1, 311-325.	0.1	0

#	ARTICLE	IF	CITATIONS
91	Are circulating tumor cells (CTCs) a feasible tool for predicting disease recurrence and survival in nonmetastatic (M0) colorectal cancer (CRC)?. Journal of Clinical Oncology, 2015, 33, 650-650.	0.8	0
92	Using mutational load in next generation sequencing (NGS) to identify mismatch repair (MMR) deficiency in colorectal cancer (CRC).. Journal of Clinical Oncology, 2015, 33, 3565-3565.	0.8	0
93	Metastatic colorectal cancer (mCRC) treatment: A high-volume, single-center, real-life experience.. Journal of Clinical Oncology, 2016, 34, 733-733.	0.8	0
94	Induction treatment with FOLFOXIRI + bevacizumab (BV) followed by chemo-radiotherapy (CRT) + BV and surgery in locally advanced rectal carcinoma (LARC): The phase II TRUST trial.. Journal of Clinical Oncology, 2016, 34, 673-673.	0.8	0
95	Randomized phase II study of first-line FOLFOX plus panitumumab (pan) versus 5FU plus pan in elderly RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts): The PANDA study.. Journal of Clinical Oncology, 2016, 34, TPS3627-TPS3627.	0.8	0
96	Genetic variants of <i>Pin1</i> to predict benefit from irinotecan and oxaliplatin based treatment in patients with metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2016, 34, 11589-11589.	0.8	0
97	Results of the phase II TRUST trial of induction treatment with FOLFOXIRI + bevacizumab (BV) followed by chemo-radiotherapy (CRT) plus BV and surgery in locally advanced rectal carcinoma (LARC).. Journal of Clinical Oncology, 2016, 34, 3615-3615.	0.8	0
98	Angiogenesis inhibitor bevacizumab and symptomatic anal ulcers in metastatic colorectal cancer patients: A single center experience.. Journal of Clinical Oncology, 2017, 35, e15042-e15042.	0.8	0
99	Genetic variants within the glucocorticoids related genes to predict outcome in patients with metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2018, 36, 12098-12098.	0.8	0
100	Molecular characterization of appendiceal cancer and comparison with right-sided (R-CRC) and left-sided colorectal cancer (L-CRC).. Journal of Clinical Oncology, 2018, 36, 3611-3611.	0.8	0
101	Genetic variations in the $\hat{I}^2M/HLA-E$ immunomodulatory complex to predict outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with first line FOLFIRI/Cetuximab: Data from the phase III FIRE-3 trial.. Journal of Clinical Oncology, 2018, 36, 12107-12107.	0.8	0
102	The impact of Th17 cell pathway-related genetic variants in metastatic colorectal cancer patients treated with bevacizumab-based chemotherapy.. Journal of Clinical Oncology, 2018, 36, e15578-e15578.	0.8	0
103	Abstract 2614: Macrophage erythroblast attacher (MAEA) polymorphisms are associated with clinical outcome in TRIBE study mCRC patients treated with 5-fluorouracil/bevacizumab-based therapy. , 2018, ,		0
104	Th17 cell pathway-related genetic variants in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC, and FIRE-3.. Journal of Clinical Oncology, 2019, 37, 594-594.	0.8	0
105	Genetic variants in the lipopolysaccharide (LPS) receptor complex and TLR4 expression levels to predict efficacy of cetuximab (cet) in patients (pts) with metastatic colorectal cancer (mCRC): Data from the FIRE-3 phase III trial.. Journal of Clinical Oncology, 2019, 37, 564-564.	0.8	0
106	Polymorphisms in the telomerase complex to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from TRIBE and FIRE-3 phase III trials.. Journal of Clinical Oncology, 2019, 37, 566-566.	0.8	0
107	Comprehensive molecular profiling of signet-ring-cell carcinoma (SRCC) from the stomach and colon.. Journal of Clinical Oncology, 2019, 37, 63-63.	0.8	0
108	Genetic variants in RNA binding protein (RBP) to predict outcome in metastatic colorectal cancer (mCRC): Data from FIRE-3, TRIBE, and MAVERICC trials.. Journal of Clinical Oncology, 2019, 37, 3545-3545.	0.8	0

#	ARTICLE	IF	CITATIONS
109	Association of genetic variations within the T-cell costimulatory LIGHT gene with outcome in stage II and III colon cancer.. Journal of Clinical Oncology, 2019, 37, 2633-2633.	0.8	0
110	How I Treat Early-Stage Colon Cancer With Adjuvant Therapy: Who and How Long?. , 2019, , .		0
111	Molecular characterization of appendiceal goblet cell carcinoid.. Journal of Clinical Oncology, 2020, 38, 231-231.	0.8	0
112	Genetic variants in immunogenic cell death (ICD) relating genes to predict outcome in metastatic colorectal cancer (mCRC): Data from FIRE-3, TRIBE and MAVERICC trials.. Journal of Clinical Oncology, 2020, 38, 187-187.	0.8	0
113	Comprehensive molecular analysis of microsatellite-stable (MSS) tumors with high mutational burden in gastrointestinal (GI) cancers.. Journal of Clinical Oncology, 2020, 38, 3631-3631.	0.8	0
114	Somatic alterations of NF1 in colorectal cancer.. Journal of Clinical Oncology, 2020, 38, 4066-4066.	0.8	0
115	Molecular correlates of PD-L1 expression in patients (pts) with gastroesophageal (GE) cancers.. Journal of Clinical Oncology, 2020, 38, 4558-4558.	0.8	0
116	Hippo pathway signaling associated with immune cell trafficking in colorectal cancer.. Journal of Clinical Oncology, 2022, 40, 156-156.	0.8	0
117	The role of germline polymorphisms in genes involved in the antioxidant system to predict the efficacy of cetuximab for patients with metastatic colorectal cancer (mCRC) enrolled in FIRE-3 trial.. Journal of Clinical Oncology, 2022, 40, 143-143.	0.8	0
118	LRP1B and GRM3 expression in colorectal cancer.. Journal of Clinical Oncology, 2022, 40, 177-177.	0.8	0
119	Identification and characterization of recurrent neoantigens in upper gastrointestinal (GI) cancers.. Journal of Clinical Oncology, 2022, 40, 246-246.	0.8	0
120	Abstract 2864: MAEA (macrophage erythroblast attacher) suppresses migration, invasion and enhances chemosensitivity in colorectal cancer cell lines. , 2019, , .		0
121	Molecular correlates of <i>MAEA</i> expression in colorectal cancer (CRC).. Journal of Clinical Oncology, 2022, 40, 3128-3128.	0.8	0
122	Comprehensive profiling of clock genes expression in colorectal cancer (CRC).. Journal of Clinical Oncology, 2022, 40, 3129-3129.	0.8	0
123	Characterization of TIM3 and its ligands in colorectal cancer.. Journal of Clinical Oncology, 2022, 40, 3547-3547.	0.8	0
124	Predictive value of <i>CDC37</i> gene expression for targeted therapy in metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2022, 40, 3586-3586.	0.8	0
125	Predictive value of <i>MAOB</i> gene expression for targeted therapy in patients (pts) with metastatic colorectal cancer (mCRC) enrolled in CALGB (Alliance)/SWOG 80405.. Journal of Clinical Oncology, 2022, 40, 3580-3580.	0.8	0
126	Comprehensive characterization of <i>PTPRT</i> expression in colorectal cancer (CRC).. Journal of Clinical Oncology, 2022, 40, 3538-3538.	0.8	0

#	ARTICLE	IF	CITATIONS
127	<i>DEFB1</i> gene expression and the molecular landscape of colorectal cancer (CRC).. Journal of Clinical Oncology, 2022, 40, 3523-3523.	0.8	0
128	Landscape of endocytosis pathway in colorectal cancer (CRC).. Journal of Clinical Oncology, 2022, 40, 3148-3148.	0.8	0
129	Characterization of <i>NY-ESO-1</i> gene expression in gastric cancer (GC).. Journal of Clinical Oncology, 2022, 40, 4046-4046.	0.8	0